The drug companies have aggressively marketed their ATTR drugs -- amyloidosis, causing left ventricle thickening among other things. They are advertising this because the drug costs about $250k/year and they make gigantic profits.
However, MOST people with diastolic heart failure do not have amyloidosis. They simply have fibrosis. If Leronlimab can address that type of fibrosis, this is a huge unmet medical need.